Chelsea has over 40 years’ experience in the life sciences sector, with a wide-ranging portfolio that includes laboratory instrumentation, point of care devices and veterinary equipment. Chelsea’s past work for biotech companies focused on contract design and manufacture, featuring complex optical design for critical applications requiring sensitive and repeatable results.
Brightline Dx is a joint venture formed by two highly innovative UK companies, Stream Bio and Chelsea Technologies, to combine novel technologies and create a unique platform that can be applied to a wide range of diagnostic targets. The Joint Venture’s immediate focus is a highly sensitive saliva based Covid-19 test, capable of rapid identification of Covid-19, including detection of low viral loads typically found in asymptomatic carriers. To find out more about this and other medical applications, please visit the Brightline Diagnostics website – www.brightlinedx.com
Through Brightline, Chelsea offer a bespoke diagnostic test development service for the detection of waterborne pathogens and invasive species.
For more information, contact Elizabeth Paull at email@example.com